Apnimed Inc APMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $18.95
- Day Range
- $18.23–19.83
- 52-Week Range
- $16.12–35.29
- Bid/Ask
- $17.00 / $20.03
- Shares Outstanding
- 41.63M
- Market Cap
- $809.30M
- Volume/Avg
- 365,364 / 506,224
Key Statistics
- Price/Earnings (Normalized)
- 4.19
- Price/Sales
- 4.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.apnimed.com
Valuation
|
Metric
|
APMD
|
|---|---|
Price/Earnings (Normalized) | 4.19 |
Price/Book Value | — |
Price/Sales | 4.66 |
Price/Cash Flow | 5.41 |
Price/Earnings
APMD
Financial Strength
|
Metric
|
APMD
|
|---|---|
Quick Ratio | 4.88 |
Current Ratio | 5.19 |
Interest Coverage | — |
Quick Ratio
APMD
Profitability
|
Metric
|
APMD
|
|---|---|
Return on Assets (Normalized) | 74.40% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
APMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|gsD<>h | LOCK|Z&K& | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|LP&Y$! | LOCK|&B>^q | $83B | |||
| Moderna Inc
MRNA
| LOCK|?^X^#WX | LOCK|kWX | $79B | |||
| argenx SE ADR
ARGX
| LOCK|lK?>rtH | LOCK|LDW | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bC^VRJp | LOCK|PhF | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|P^S>#tL | LOCK|q%n$< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|CRr<S#G | LOCK|#%R? | $29B | |||
| Incyte Corp
INCY
| LOCK|FwVfZ?! | LOCK|TW | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?VHCJw | LOCK|%B^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#bL?QT< | LOCK|r< | $13B |
United States